NCT04278885

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

Factor XII-associated Cold Autoinflammatory Syndrome (FACAS) Linked to Kallikrein-kinin Pathology: Proof of Concept Treatment With Lanadelumab (DX-2930)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Charite University, Berlin, Germany · Academic / Other
• Sex: All
• Age: 12 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to assess the effects and safety of Lanadelumab in patients with FXII-associated cold autoinflammatory syndrome (FACAS).

Detailed description

Factor XII is a serine protease with diverse functions that participates in coagulation, fibrinolysis, complement and contact system activation. So far, mutations in the factor XII gene were linked to the rare coagulation disorder Hagemann factor deficiency and hereditary angioedema (FXII-HAE). The investigators recently identified a novel FXII mutation in a 4-generation family with profound contact system activation and an autoinflammatory clinical phenotype. Lanadelumab is a specific kallikrein Inhibitor that is known to prevent clinical symptoms and contact system activation in hereditary angioedema. This study aims at assessing the clinical effects and safety of Lanadelumab in patients with FXII-associated cold autoinflammatory syndrome (FACAS).

Conditions

• Hereditary Autoinflammatory Disease

Interventions

Type	Name	Description
DRUG	Lanadelumab	300mg Lanadelumab s.c. administration every 2 weeks

Timeline

• Start date: 2020-10-05
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2020-02-20
• Last updated: 2024-01-08

Locations

1 site across 1 country: Germany